Overview
The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment
Status:
Unknown status
Unknown status
Trial end date:
2008-08-01
2008-08-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
To evaluate whether treatment with Estradiol supplementation during the luteal phase improves IVF outcomes Patients undergoing IVF treatment with controlled ovarian hyperstimulation using a GnRH analog will receive 4 mg estradiol valerate in the luteal phase.Patient's followup will include E2 progesterone and BHCG 14 days after embryo transfer and vaginal ultrasound on day 21 and 28 after embryo transferPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Assaf-Harofeh Medical CenterTreatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate
Criteria
Inclusion Criteria:- Women treated for infertility with controlled ovarian hyperstimulation using daily
GnRH agonist
Exclusion Criteria:
- Women younger then 18 or older then 40
- Women with systemic disease
- Women with a family or personal history of thromboembolic event